Abstract: The invention describes novel PDE3 inhibitors for treating a cardiovascular disease including myxomatous mitral valve disease, congestive heart failure and/or asymptomatic heart failure in animals, particularly canines.

Abstract: Provided herein are immunogenic compositions that may be used, in some aspects, to induce an immune response against an Ehrlichia such as Ehrlichia canis. In some embodiments, the immunogenic composition comprises an E. canis bacterin and/or adjuvant, such as for example an emulsion or liposomal adjuvant. Related methods such as for diagnosis of or vaccination against ehrlichiosis are also provided.

Abstract: The disclosure relates generally to canine antibody variants and uses thereof. Specifically, the disclosure relates to mutations in the constant region of canine antibody for improving its half-life and other characters.

Abstract: The invention relates generally to feline antibody variants and uses thereof. Specifically, the invention relates to mutations in the constant region of feline antibody for improving its half-life and other characters.

Abstract: An intra-orifice medicament delivery system and formation method involve a housing defining an inner chamber extending along a longitudinal axis, with the chamber wall defining one or more openings therethrough. A retention arrangement extends from the housing, and is adapted to removably retain the housing within a bodily orifice defined by an orifice wall. An osmotic delivery device is disposed within the chamber and includes an osmogen portion and medicament-including portion disposed within a semipermeable membrane. The osmogen portion expands and applies pressure to the medicament-including portion in response to absorption of a liquid from within the bodily orifice permeating through the semipermeable membrane.

Abstract: The invention relates to injectable pharmaceutical compositions, methods of use and formulation, wherein the compositions comprise: one or more water soluble complexes, each complex comprising a cyclodextrin or a cyclodextrin derivative and a hydrophobic drug; at least one preservative; and at least one co-solvent. The compositions are effectively preserved in accordance with the European Pharmacopoeia 2011 Test for Efficacy of Antimicrobial Preservation, satisfying at least the B criteria as it applies to parenterals, and the United States Pharmacopeia 2011 Guidelines for Antimicrobial Effectiveness Testing, satisfying the criteria for Category 1 (injectable) products.

Abstract: The present disclosure encompasses novel anti-NGF antibodies, antigen binding proteins and polynucleotides encoding the same. The disclosure further provides use of the novel antibodies, antigen binding proteins and/or nucleotide of the invention for the treatment of NGF related disorders, particularly in for the management of pain.

Abstract: This invention relates to adjuvant formulations comprising various combinations of triterpenoids, sterols, immunomodulators, polymers, and Th2 stimulators; methods for making the adjuvant compositions; and the use of the adjuvant formulations in immunogenic and vaccine compositions with different antigens. This invention further relates to the use of the formulations in the treatment of animals.

Abstract: The present disclosure encompasses novel anti-NGF antibodies, antigen binding proteins and polynucleotides encoding the same. The disclosure further provides use of the novel antibodies, antigen binding proteins and/or nucleotide of the invention for the treatment of NGF related disorders, particularly in for the management of pain.

Abstract: An apparatus for singulating organisms includes a chute, an output nozzle, and a valve. The chute includes a first chute end that is open to receive a plurality of organisms and a second chute end. The output nozzle is formed in a funnel shape and has a first nozzle end and a second nozzle end. The valve is attached to the second chute end and the first nozzle end. The valve is movable to a range of positions including an open position and a closed position. One organism travels to and blocks the second nozzle end and another organism travels to the second chute end. The organism that is positioned at the output nozzle is discharged from the singulating device upon movement of the valve from the open position to the closed position.

Abstract: The present application relates to an avian cell line capable of supporting viral growth of Marek's Disease Virus (MDV), including Herpes Virus of Turkeys (HVT), methods of producing such cell lines, and therapeutic uses of the cell lines and resulting vaccines.

Abstract: The drinking water-based avian coccidiosis vaccine formulation and delivery system is structured to deliver a vaccine containing live Eimeria oocysts to poultry house brood chamber chicks. The vaccine is delivered to the chicks in a diluted form through the poultry house drinking water system. The chicks are inoculated with the drinking water-based avian coccidiosis vaccine when they consume the water containing the vaccine. The timing of the chicks' drinking water access to the diluted drinking water vaccine is critical. During the inoculation process, water is temporarily withheld from the chicks for a waiting period of about 3-5 hours, and access to the diluted drinking water-based vaccine is limited to an accessibility period of about 2 hours. Additionally, metering valves and/or terminal metering valve assemblies are manually or automatically closed when the when the drinking water lines are fully charged with the diluted vaccine.

Abstract: Defined herein are immunomodulating Formula (1) compounds, wherein R1, R2 and W are as defined herein, stereoisomers thereof, and pharmaceutically acceptable salts thereof; and compositions comprising said compounds. The invention also includes methods for treating an inflammatory and/or immunological disease or disorder in an animal by administering a therapeutically effective amount of a Formula (1) compound, stereoisomer thereof, and a pharmaceutically acceptable salt thereof; or use of said compound of Formula (1) to prepare a medicament for treating an inflammatory and/or immunological disease or disorder in an animal.

Abstract: Defined herein are immunomodulating Formula (1) compounds stereoisomers thereof, and pharmaceutically acceptable salts thereof; wherein R0, R1, R2, R10, W, Ring C and n are as defined herein, stereoisomers thereof, and pharmaceutically acceptable salts thereof; and compositions comprising said compounds. The invention also includes methods for treating an inflammatory and/or immunological disease or disorder in an animal by administering a therapeutically effective amount of a Formula (1) compound, stereoisomer thereof, and a pharmaceutically acceptable salt thereof; or use of said compound of Formula (1) to prepare a medicament for treating an inflammatory and/or immunological disease or disorder in an animal.

Abstract: Defined herein are immunomodulating Formula (1) compounds, wherein R, R0, R1, R2 and W are as defined herein, stereoisomers thereof, and pharmaceutically acceptable salts thereof; and compositions comprising said compounds. The invention also includes methods for treating or preventing an inflammatory and/or immunological disease or disorder in an animal by administering a therapeutically effective amount of a Formula (1) compound, stereoisomer thereof, or pharmaceutically acceptable salt thereof; or use of said Formula (1) compound to prepare a medicament for treating or preventing an inflammatory and/or immunological disease or disorder in an animal.

Abstract: The present invention provides compositions and methods related to equine live-attenuated influenza vaccines. In one aspect, the invention relates to a composition comprising a multivalent equine live-attenuated influenza vaccine comprising a first live-attenuated influenza virus expressing one or more antigens of a clade 1 H3N8 equine influenza virus; and a second live-attenuated influenza virus expressing one or more antigens of a clade 2 H3N8 equine influenza virus, wherein the second live-attenuated influenza virus expresses HA, NA, or a combination thereof of A/equine/Lancashire/1/2016 H3N8.

Abstract: The present invention provides a method of determining the identity and/or amount of an anti-IL-31 antibody in a sample. Such a method includes incubating a sample comprising an anti-IL-31 antibody with at least one mimotope selected from a feline IL-31 mimotope, a canine IL-31 mimotope, a horse IL-31 mimotope, and a human IL-31 mimotope; and determining the identity and/or quantity of the anti-IL-31 in the sample.

Abstract: The present invention is directed to novel nucleotide and amino acid sequences of Porcine Epidemic Diarrhea Virus (“PEDV”), including novel genotypes thereof, all of which are useful in the preparation of vaccines for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against multiple swine PEDV genotypes and isolates. Diagnostic and therapeutic polyclonal and monoclonal antibodies are also a feature of the present invention, as are infectious clones useful in the propagation of the virus and in the preparation of vaccines. Particularly important aspects of the invention include polynucleotide constructs that replicate in tissue culture and in host swine. The invention also provides for novel full length PEDV genomes that can replicate efficiently in host animals and tissue culture.